Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-15

Milestone Pharmaceuticals Inc. (MIST) Stock Forecast Oct. 15, 2026

Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D Neutral Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Middle 30% of 5111 stocks scored
Rank correlation · 90D 7.0% Spearman, 358 dates
Market Cap $112M small-cap · #60 of 60 peers
Summary

Milestone Pharmaceuticals Inc. (MIST) stock forecast summary

On Oct. 15, 2026, MIST is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5111 stocks scored that day.

Milestone Pharmaceuticals Inc. is a small-cap company with a market capitalization of $112M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its ROE of -461.1% is the lowest of the 36 peers that report one.

For MIST, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 7.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, MIST included.

Follow MIST free
Price

MIST price chart and AI forecast

MIST
Cross-section · 2026-10-15

How MIST ranks among 5111 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Milestone Pharmaceuticals Inc. (MIST) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.

Valuation & Market

MetricMISTIndustry medianRank
Market Cap $112M $12.63B 60/60
P/B Ratio 6.15x 7.20x 24/41
EPS $-0.76 – –
Book Value/Share $0.13 – –
FCF/Share $-0.43 – –

Profitability & Margins

MetricMISTIndustry medianRank
ROE -461.1% 6.3% 36/36
ROA -46.3% -1.2% 36/41
ROIC -49.2% -0.4% 35/44

Financial Health

MetricMISTIndustry medianRank
Current Ratio 8.13x 3.06x 13/56
Quick Ratio 7.92x 1.71x 2/42
D/E Ratio 8.97x 1.29x 2/46
Financial Leverage 9.97x 2.16x 2/46
Interest Coverage -12.0x 0.7x 24/35
Working Capital $158M $945M 50/56

Cash Flow

MetricMISTIndustry medianRank
Operating Cash Flow -$61M $183M 38/56
Free Cash Flow -$62M $164M 31/47
Capital Spending -$360K -$46M 6/47

Income Statement

MetricMISTIndustry medianRank
Operating Income -$78M $32M 28/48
Net Income -$84M -$38M 25/43
R&D Expense $16M $548M 55/55

Dividend & Shareholder Information

MetricMISTIndustry medianRank
Shares Outstanding 142M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$180M99.3% of assets
Cash & Short-term Investments$170M93.4% of assets
Accounts Receivable$3M1.5% of assets
Inventory$5M2.6% of assets
Total Liabilities$163M90.0% of assets
Short-term Debt$14M7.6% of assets
Quarterly Financial Reports

MIST quarterly financials and insider trading

Industry Peers · Pharmaceutical Preparations

Milestone Pharmaceuticals Inc. (MIST) industry peers

Companies classified under the same SEC industry code as Milestone Pharmaceuticals Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
MIST Milestone Pharmaceuticals Inc. ▶ $112M – 6.2x
LLY Eli Lilly & Co ▶ $1.14T 40.6x 115.8x
JNJ Johnson & Johnson ▼ $611.90B 29.5x 7.2x
ABBV Abbvie Inc. ▶ $500.75B 73.2x –
MRK Merck & Co., Inc. ▶ $363.59B 117.9x 8.7x
NVS Novartis Ag ▼ $280.27B 8.8x –
AZN Astrazeneca Plc ▼ $251.15B 11.7x –
ABT Abbott Laboratories ▼ $182.04B 29.3x 3.5x
NVO Novo Nordisk A S ▼ $169.41B 2.8x –
PFE Pfizer Inc ▼ $166.49B 36.1x 2.0x
VRTX Vertex Pharmaceuticals Inc / Ma ▼ $126.35B 28.7x 6.2x
BMY Bristol Myers Squibb Co ▶ $121.09B 13.0x 5.4x
SNY Sanofi ▼ $98.05B – –
GSK Gsk Plc ▼ $96.58B 5.3x –
REGN Regeneron Pharmaceuticals, Inc. ▶ $80.48B 19.3x 2.5x
TEVA Teva Pharmaceutical Industries Ltd ▶ $47.45B 67.1x 6.1x
ONC Beone Medicines Ltd. ▲ $39.96B 1212.0x 7.7x
RPRX Royalty Pharma Plc ▲ $33.92B 41.6x 5.0x
ALNY Alnylam Pharmaceuticals, Inc. ▶ $31.32B 58.8x 23.1x
ZTS Zoetis Inc. ▼ $31.11B 11.9x 9.9x
TAK Takeda Pharmaceutical Co Ltd ▶ $30.24B – –
ATHE Alterity Therapeutics Ltd ▶ $25.65B – –
ZLAB Zai Lab Ltd ▶ $25.26B – 41.6x
ROIV Roivant Sciences Ltd. ▲ $24.28B – 5.7x
GMAB Genmab A/S ▶ $23.73B 1.5x –
UTHR United Therapeutics Corp ▼ $23.16B 17.7x 3.6x
INSM Insmed Inc ▶ $21.36B – 28.2x
VTRS Viatris Inc ▶ $20.03B – –
ASND Ascendis Pharma A/S ▲ $14.94B – –
JAZZ Jazz Pharmaceuticals Plc ▼ $13.61B 14.3x 2.8x
BBIO Bridgebio Pharma, Inc. ▶ $12.69B – –
CORT Corcept Therapeutics Inc ▲ $12.56B 130.6x 17.8x
SMMT Summit Therapeutics Inc. ▶ $12.07B – 19.2x
ELAN Elanco Animal Health Inc ▼ $11.27B – 1.7x
BMRN Biomarin Pharmaceutical Inc ▶ $10.67B 68.9x 1.7x
RDY Dr Reddys Laboratories Ltd ▼ $10.64B 14.0x –
MDGL Madrigal Pharmaceuticals, Inc. ▶ $10.63B – 20.3x
PTGX Protagonist Therapeutics, Inc ▶ $8.82B 172.5x 10.5x
CYTK Cytokinetics Inc ▲ $8.82B – –
AXSM Axsome Therapeutics, Inc. ▲ $8.50B – 102.0x
ARWR Arrowhead Pharmaceuticals, Inc. ▲ $8.26B – 17.8x
ABVX Abivax S.A. ▼ $7.26B – –
IONS Ionis Pharmaceuticals Inc ▲ $7.10B – 16.1x
SYRE Spyre Therapeutics, Inc. ▲ $6.93B – 6.3x
ALKS Alkermes Plc. ▲ $6.73B 44.1x 3.7x
PRAX Praxis Precision Medicines, Inc. ▲ $6.67B – 5.0x
KNSA Kiniksa Pharmaceuticals International, Plc ▼ $6.16B 86.6x 10.2x
AMRX Amneal Pharmaceuticals, Inc. ▲ $6.15B 58.3x –
BLTE Belite Bio, Inc ▲ $6.01B – 7.8x
RYTM Rhythm Pharmaceuticals, Inc. ▶ $5.97B – 58.0x
LGND Ligand Pharmaceuticals Inc ▶ $5.88B 28.6x 6.1x
BLRX Biolinerx Ltd. ▶ $5.43B – –
MIRM Mirum Pharmaceuticals, Inc. ▲ $5.19B – –
ERAS Erasca, Inc. ▲ $5.14B – 14.2x
ORKA Oruka Therapeutics, Inc. ▲ $5.08B – 4.6x
TVTX Travere Therapeutics, Inc. ▲ $5.02B – 204.8x
PTCT Ptc Therapeutics, Inc. ▲ $4.98B – –
COGT Cogent Biosciences, Inc. ▶ $4.88B – 9.2x
MANE Veradermics, Inc ▲ $4.74B – 5.8x
DNTH Dianthus Therapeutics, Inc. /De/ ▲ $4.18B – 3.6x

Where MIST sits on the market map

Life Sciences · Pharmaceutical Preparations
Explore the map →
News

Milestone Pharmaceuticals Inc. (MIST) stock news

Loading...

FAQ

Milestone Pharmaceuticals Inc. (MIST) stock forecast FAQ

What is the Milestone Pharmaceuticals Inc. (MIST) stock forecast?

On Oct. 15, 2026, MIST is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5111 stocks scored that day.

How accurate are Milestone Pharmaceuticals Inc. stock predictions?

For MIST, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 7.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Milestone Pharmaceuticals Inc. forecasts updated?

Milestone Pharmaceuticals Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.

Which companies are Milestone Pharmaceuticals Inc.'s industry peers?

60 issuers in our coverage, MIST included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.